Tong Xiang, Wang Dongguang, Liu Sitong, Ma Yao, Li Zhenzhen, Tian Panwen, Fan Hong
Department of Respiratory and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, People's Republic of China.
The Center of Gerontology and Geriatrics, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2018 Jan 30;13:409-418. doi: 10.2147/COPD.S152655. eCollection 2018.
Many studies have found that YKL-40 may play an important pathogenic role in COPD. However, the results of these studies were inconsistent. Therefore, we performed a systematic review and meta-analysis to investigate the role of YKL-40 in COPD.
We performed a systematic literature search in many database and commercial internet search engines to identify studies involving the role of YKL-40 in patients with COPD. The standardized mean difference (SMD) and Fisher's -value with its 95% confidence interval (CI) were used to investigate the effect sizes.
A total of 15 eligible articles including 16 case-control/cohort groups were included in the meta-analysis. The results indicated that the serum YKL-40 levels in patients with COPD were significantly higher than those in healthy controls (SMD =1.58, 95% CI =0.68-2.49, =0.001), and it was correlated with lung function (pooled =-0.32; =-0.33; <0.001). The results of subgroup analysis found that the serum YKL-40 levels were statistically different between the exacerbation group and the stable group in patients with COPD (SMD =1.55, 95% CI =0.81-2.30, <0.001). Moreover, the results indicated that the sputum YKL-40 levels in patients with COPD were also significantly higher than those in healthy controls (SMD =0.70, 95% CI =0.10-1.30, =0.022).
The current study suggests that YKL-40 may be implicated in bronchial inflammation and remodeling in COPD and may be considered as a useful biomarker for COPD diagnosis and monitoring.
许多研究发现，YKL-40可能在慢性阻塞性肺疾病（COPD）中发挥重要的致病作用。然而，这些研究结果并不一致。因此，我们进行了一项系统评价和荟萃分析，以研究YKL-40在COPD中的作用。
我们在多个数据库和商业互联网搜索引擎中进行了系统的文献检索，以确定涉及YKL-40在COPD患者中作用的研究。采用标准化均数差（SMD）和Fisher's P值及其95%置信区间（CI）来研究效应大小。
荟萃分析共纳入15篇符合条件的文章，包括16个病例对照/队列组。结果表明，COPD患者血清YKL-40水平显著高于健康对照组（SMD = 1.58，95%CI = 0.68 - 2.49，P = 0.001），且与肺功能相关（合并r = -0.32；r = -0.33；P < 0.001）。亚组分析结果发现，COPD患者急性加重组和稳定组血清YKL-40水平存在统计学差异（SMD = 1.55，95%CI = 0.81 - 2.30，P < 0.001）。此外，结果表明，COPD患者痰液YKL-40水平也显著高于健康对照组（SMD = 0.70，95%CI = 0.10 - 1.30，P = 0.022）。
当前研究表明，YKL-40可能参与COPD的支气管炎症和重塑，可被视为COPD诊断和监测的有用生物标志物。
